Valuation : Theralase Technologies Inc.

Market Cap 53.22M 38.39M 32.96M 30.85M 28.25M 3.67B 53.37M 365M 143M 1.85B 144M 141M 6.12B P/E 2026 *
-18x
P/E 2027 * 9x
Enterprise Value 53.22M 38.39M 32.96M 30.85M 28.25M 3.67B 53.37M 365M 143M 1.85B 144M 141M 6.12B EV / Sales 2026 *
66.4x
EV / Sales 2027 * 1.57x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day-2.70%
1 week-5.26%
Current month-36.84%
1 month-30.77%
3 months-20.00%
6 months-36.84%
Current year+9.09%
1 week 0.18
Extreme 0.18
0.2
1 month 0.18
Extreme 0.175
0.3
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
07/08/26 Option

Director

1,000,000 0.3382%
07/08/26 Option

Chief Executive Officer

1,000,000 0.3382%
07/08/26 Option

Director

1,000,000 0.3382%
Change 5-day change 1-year change 3-year change Capi.($)
-2.70%-5.26%-16.28%-26.53% 38.39M
+0.13%+1.19%+28.52%+42.38% 1.43B
+9.27%+38.66%-1.49%-30.67% 244M
-1.90%-7.59%-25.54%-34.41% 51.23M
Average +1.20%-2.98%-3.70%-12.31% 440.52M
Weighted average by Cap. +1.27%+0.41%+21.82%+28.53%

Financials

2026 *2027 *
Net sales 802K 579K 497K 465K 426K 55.25M 804K 5.51M 2.15M 27.85M 2.17M 2.13M 92.16M 33.89M 24.45M 20.98M 19.65M 17.99M 2.33B 33.98M 233M 90.94M 1.18B 91.78M 89.8M 3.89B
Net income -4.2M -3.03M -2.6M -2.43M -2.23M -289M -4.21M -28.83M -11.27M -146M -11.38M -11.13M -483M 6.83M 4.93M 4.23M 3.96M 3.63M 471M 6.85M 46.89M 18.33M 237M 18.5M 18.1M 785M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
27/08/26 CA$0.1800 -2.70% 326,577
26/08/26 CA$0.1850 -2.63% 496,508
25/08/26 CA$0.1900 0.00% 559,121
24/08/26 CA$0.1900 +2.70% 326,571
21/08/26 CA$0.1850 -2.63% 344,702
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1800CAD
Average target price
0.7000CAD
Spread / Average Target
+288.89%

Quarterly revenue - Rate of surprise